U-ONVO

Q:ONVO - ORGANOVO HLDGS INC - http://www.organovo.com

03:24:18 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
ONVO - Q	0.5	1.09	·	1.28	34.4	1.15	+0.03	2.7	579.0	632	1,534	1.10 1.29 1.09	2.23 0.8911	Apr 18	Apr 15	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 1534

More trades...

Time ET	Ex	Price	Change	Volume
19:47:26	Q	1.17	0.05	1
19:26:12	Q	1.10	-0.02	15
17:42:44	Q	1.12		100
17:38:00	Q	1.12		5
17:12:20	Q	1.18	0.06	17
17:07:49	Q	1.12		5
16:16:16	Q	1.12		18
16:01:52	Q	1.12		30
16:00:41	Q	1.13	0.01	5
16:00:00	Q	1.15	0.03	50

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-15 08:05	U:ONVO	News Release200	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
2024-01-25 08:05	U:ONVO	News Release200	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn ¢ € ™s and Colitis Congress
2024-01-09 08:05	U:ONVO	News Release200	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn ¢ € ™s and Colitis Congress
2023-12-06 08:05	U:ONVO	News Release200	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
2023-11-13 08:05	U:ONVO	News Release200	CORRECTION ¢ € “ Organovo Highlights FXR314 Combination Therapy Potential and Plan
2023-11-08 08:06	U:ONVO	News Release200	Organovo Highlights FXR314 Combination Therapy Potential and Plan
2023-09-08 12:46	U:ONVO	News Release200	Organovo to Participate in the H.C. Wainwright Global Investment Conference
2023-08-23 08:05	U:ONVO	News Release200	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Date ET

Symbol

Type

Headline

2024-04-15 08:05

U:ONVO

News Release

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

2024-01-25 08:05

U:ONVO

News Release

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn ¢ € ™s and Colitis Congress